Congratulations to @ArvinasInc who will be honored with the Bioscience Company award at our 22nd Annual Health Care & Life Sciences Awards, presented by @ynhhealth
Wednesday, July 24th at 3:30pm
Canal Dock Boathouse
Register now to attend: https://t.co/sUr0WZDqpY
This Friday, March 29, join @GSKUS and other leaders in health care for a @statnews discussion about how we can ensure the patient voice is included in conversations about the significant medical breakthroughs of today. Register for the virtual event: https://t.co/c2QrAAJk0n
More transparency on the PBM industry is important, but not enough. Even as the FTC, state AGs, federal and state lawmakers look under the hood of the broken PBM model, the big #PBMs are finding new ways to drive out competition and drive up costs.
The EPIC Act is simple: It eliminates the #IRA "pill penalty" so the government doesn't pick winners and losers among different categories of medicine. Read more here: https://t.co/vIqUqRRRVK
During #RareDiseaseDay, @CTBio noted the diagnostic odyssey for patients can take 7 years, but whole genome sequencing can cut that to weeks or days. “It helps patients and families unbelievably, but it also saves the healthcare system a huge amount of money,” Pescatello says.
Don't miss out! Tomorrow, @ITIFdc will hold an expert briefing on Capitol Hill to share its new report on policy threats to America's global leadership in the biopharmaceutical industry.
Learn more and register here: https://t.co/DK8X8XfS23
This #AmericanHeartMonth, neurology and emergency room nurse @sharonlamberton shares her experience advocating for new cardiovascular treatments and why it's important that the U.S. policy environment support access to these medicines. https://t.co/M9lJXdlKq0
#MA patients rely on public-private sector collaboration to bring much-needed medications, including new treatments for #lupus, to the #Rx counter. @POTUS's use of #MarchInRights —which threatens to seize drug patents—will deter this partnership that delivers innovative cures.
If a White House proposal to seize patents prevails, it will be a “disaster” for American workers and consumers. Learn more. #MarchInRights#BayhDole@weworkforhealth https://t.co/CtiTG1zVPE From @IBTimes
Our CEO Rachel King's op-ed exposes the danger of short-sighted U.S. policies, risking future medical breakthroughs. Government interference threatens life-changing drugs. Stay informed on #biotech innovation impact and preserve the progress made thus far. 💊🔬✨ @RachelKingBio https://t.co/IBDypOqUAm
71 novel treatments & vaccines were approved in the U.S. last year to help tackle a variety of diseases and conditions, including:
➡️Alzheimer’s
➡️RSV
➡️Postpartum depression
➡️Sickle Cell Disease
➡️Cancer
➡️ALS
➡️Genetic diseases, like hemophilia A
https://t.co/7TzIkmQk8Y
.@WWFHCT Chair explains why the #IRA’s so-called drug price “negotiation” is anything but. Instead, it’s a take-it-or-leave-it form of gov’t #pricecontrols, which don’t work. https://t.co/esn9RfVNYL
President Biden announced the first 10 drugs for price controls, and he’s exaggerating the benefits while ignoring the larger damage.
https://t.co/3Hk2MXU7PU
PBMs can steer you toward pharmacies that make them more money. How is that possible? Because they own pharmacies, too. See how these middlemen are putting profits before your health: https://t.co/9fTvQnlzGx
Newsflash: the #IRA’s drug price controls will threaten critical research into the cures and treatments that CT patients living with chronic or rare diseases hope for. @CMSGov’s initial #IRA
drug list is not worth celebrating.
Soon, the government will release the first list of medicines for price setting, focusing on short-term political objectives vs. the real-world needs of patients — and in the process, ignore existing savings from private sector negotiation & competition: https://t.co/XsBdeK7lZr
Government #PriceSetting for RX drugs is not the answer. We need lawmakers to advocate for policies that support a strong biotechnology industry & result in impactful cost savings for CT patients. Policies that incentivize robust pharmaceutical research & improve patient access.
Research and investment is a huge part of CT's growing bioscience economy- CT has over 45,000 residents employed in an industry-supported job. We cannot let policies like the IRA price setting mechanisms set us back in developing CT's bio industry.
Gov't-mandated price setting in Medicare is not the solution patients need. #ICYMI, data from WWFH & @VitalTransform illustrates the impact of such policies – hundreds of medicines never created, thousands of jobs lost across the economy. Read the report: https://t.co/mmg0mqNs2x